COVID-19 May Pose Blood Clot Risk in Pregnant Women

New Endocrinology cover

COVID-19 may increase the risk of blood clots in women who are pregnant or taking estrogen with birth control or hormone replacement therapy, according to a new manuscript published in the Endocrine Society’s journal, Endocrinology.

One of the many complications of COVID-19 is the formation of blood clots in previously healthy people. Estrogen increases the chance of blood clots during pregnancy and in women taking birth control pills or hormone replacement therapy. If infected with COVID-19, these women’s risk of blood clotting could be even higher, and they may need to undergo anticoagulation therapy or to discontinue their estrogen medicines.

“Research that helps us understand how the coronavirus causes blood clots may also provide us with new knowledge regarding how blood clots form in other settings and how to prevent them.” – Daniel I. Spratt, MD, of Maine Medical Center in Portland, Maine, and Tufts University School of Medicine in Boston, Mass.

“During this pandemic, we need additional research to determine if women who become infected with the coronavirus during pregnancy should receive anticoagulation therapy or if women taking birth control pills or hormone replacement therapy should discontinue them,” said the study’s corresponding author, Daniel I. Spratt, MD, of Maine Medical Center in Portland, Maine, and Tufts University School of Medicine in Boston, Mass. “Research that helps us understand how the coronavirus causes blood clots may also provide us with new knowledge regarding how blood clots form in other settings and how to prevent them.”

Researching and understanding the cause of blood clotting in COVID-19, including the intersecting effects of estrogen therapy or pregnancy, has several hurdles and will require innovative animal and tissue models.

Conversations between clinicians and basic researchers and between endocrinologists and hematologists are necessary to explore potential interactions between SARS-CoV-2—the virus that causes COVID-19—and pregnancy or estrogen therapy that could guide clinical management.

The manuscript’s co-author is Rachel J. Buchsbaum, MD, of Tufts Medical Center and Tufts University School of Medicine.

The manuscript received no external funding.

The manuscript, “COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy,” was published online, ahead of print.

You may also like

  • Trial Compares Two Gestational Diabetes Screening Methods

    There were no significant differences in health outcomes for pregnant women who were diagnosed with gestational diabetes or their babies using two different clinically recommended screening methods, according to results from a large-scale clinical trial conducted by Kaiser Permanente researchers and published in The New England Journal of Medicine. Although there is evidence that treating…

  • “Hunger Hormone” Ghrelin Affects Monetary Decision Making

    High ghrelin levels in healthy females predict more impulsive choices, researchers say Higher levels of the stomach-derived hormone ghrelin, which stimulates appetite, predict a greater preference for smaller immediate monetary rewards over larger delayed financial rewards, according to a new study presented at ENDO 2021. This research presents novel evidence in humans that ghrelin, the…

Find more in